|
|
 |
| |
|
|
|
Relationship Between the Bee Venom Therapy and Tumor Necrosis Factor-308 Variation in the Management of Rheumatoid Arthritis, a Prospective Study |
|
|
|
PP: 2707-2714 |
|
|
|
doi:10.18576/isl/120641
|
|
|
|
Author(s) |
|
|
|
E. A. Mashhoor,
A. A. Abd El-Aziz,
A. M. Metwaly,
E. S. Mohammed,
S. M. EL-Sherbini,
|
|
|
|
Abstract |
|
|
| Bee venom (BV) was traditionally used to treat various inflammatory disorders including rheumatoid arthritis (RA). The current study aims to assess the anti-arthritic effect of BV and the relation between tumor necrosis factor (TNF)-308 polymorphism and BV treatment response in RA. Methods: 50 RA patients received BV injection for 6 months, with an evaluation of erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), visual analog scale (VAS), disease activity score (DAS28-ESR), TNF-α, at baseline and after 6ms. Genotyping assay for TNF-α G308A rs1800629 gene polymorphism. Results: The mean age was 36.0 (29.0 -40.0) years; 90% were females and 10% were males with a mean disease duration 8 (5-10 years). Most of the studied patients (64%) had high disease activity and 37% had moderate disease activity with a mean 5.5 (4.7 -6.8) at baseline. Treatment with BV was associated with a significant improvement in ESR, CRP, VAS, and significant decline in the DAS28-ESR score with p-value <0.005. Most of cases achieved moderate and good EULAR response and a significant reduction of (TNFα) Level. TNF-α-308 genetic variant showed that the GG genotype (32 patients, 64 %) was more prevalent followed by AA genotypes (14 patients, 28 %). There was no difference between TNF-α G308 genotypes regarding the post-treatment response. Conclusion: Treatment with Bee venom can improve joint pain, disease activity, reduce ESR, CRP, and TNFα levels in RA patients. No difference between TNF-α G308 genotypes regarding treatment response.
|
|
|
|
|
|
|
|
